Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOR NASDAQ:CDT NASDAQ:ENSC NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.22$0.14$0.15▼$7.10$995K1.1286,634 shsN/ACDTCDT Equity$0.74-4.3%$2.64$0.69▼$610.00$3.77M1.442.70 million shs206,580 shsENSCEnsysce Biosciences$0.25+0.4%$0.39$0.23▼$2.75$3.89M0.831.26 million shs1.13 million shsSXTP60 Degrees Pharmaceuticals$1.39-2.8%$1.62$1.29▼$11.84$3.80M2.6552,462 shs74,356 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%0.00%0.00%+57.14%CDTCDT Equity-4.26%-12.45%-63.08%-94.84%-99.86%ENSCEnsysce Biosciences+0.40%-2.91%-27.47%-44.58%-89.10%SXTP60 Degrees Pharmaceuticals-2.80%-5.44%-9.74%-56.83%-88.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.22$0.14$0.15▼$7.10$995K1.1286,634 shsN/ACDTCDT Equity$0.74-4.3%$2.64$0.69▼$610.00$3.77M1.442.70 million shs206,580 shsENSCEnsysce Biosciences$0.25+0.4%$0.39$0.23▼$2.75$3.89M0.831.26 million shs1.13 million shsSXTP60 Degrees Pharmaceuticals$1.39-2.8%$1.62$1.29▼$11.84$3.80M2.6552,462 shs74,356 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%0.00%0.00%+57.14%CDTCDT Equity-4.26%-12.45%-63.08%-94.84%-99.86%ENSCEnsysce Biosciences+0.40%-2.91%-27.47%-44.58%-89.10%SXTP60 Degrees Pharmaceuticals-2.80%-5.44%-9.74%-56.83%-88.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics 0.00N/AN/AN/ACDTCDT Equity 1.00SellN/AN/AENSCEnsysce Biosciences 1.00SellN/AN/ASXTP60 Degrees Pharmaceuticals 2.00Hold$13.85896.40% UpsideCurrent Analyst Ratings BreakdownLatest BIOR, CDT, ENSC, and SXTP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.20 ➝ $3.705/20/2026SXTP60 Degrees Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/21/2026ENSCEnsysce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.203/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora Therapeutics$892K1.12N/AN/A($36.43) per share-0.01CDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/AENSCEnsysce Biosciences$5.07M0.77N/AN/A$0.63 per share0.40SXTP60 Degrees Pharmaceuticals$1.41M2.62N/AN/A($5.85) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/ACDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/AENSCEnsysce Biosciences-$10.18M-$3.35N/AN/AN/A-250.39%-766.45%-256.59%8/12/2026 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.36M-$8.92N/AN/AN/A-574.91%N/A-131.48%8/12/2026 (Estimated)Latest BIOR, CDT, ENSC, and SXTP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ENSCEnsysce Biosciences-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million5/15/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76-$1.28-$0.52-$1.28$0.44 million$0.16 million3/30/2026Q4 2025ENSCEnsysce Biosciences-$1.26-$0.75+$0.51-$0.75$0.50 million$1.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.050.05CDTCDT EquityN/A0.340.34ENSCEnsysce BiosciencesN/A0.710.71SXTP60 Degrees PharmaceuticalsN/A3.342.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%CDTCDT Equity3.29%ENSCEnsysce Biosciences5.63%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics51.08%CDTCDT Equity10.78%ENSCEnsysce Biosciences2.80%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics1204.52 million2.21 millionNo DataCDTCDT Equity34.86 million4.33 millionNot OptionableENSCEnsysce Biosciences1015.37 million14.94 millionNot OptionableSXTP60 Degrees Pharmaceuticals32.66 million2.61 millionNot OptionableBIOR, CDT, ENSC, and SXTP HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with BabesiosisMay 26, 2026 | globenewswire.comHC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)May 21, 2026 | msn.com60 Degrees Pharmaceuticals Announces First Quarter 2026 ResultsMay 15, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowApril 3, 2026 | zacks.comInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comFInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comF60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.com60 Degrees Pharmaceuticals Updates Opinion for ATM ProgramMarch 14, 2026 | theglobeandmail.comWhat's going on with 60 Degrees Pharmaceuticals on Friday?March 13, 2026 | msn.com60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical TrialMarch 11, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAFebruary 24, 2026 | insidermonkey.com60 Degrees Pharmaceuticals (SXTP) price target increased by 300.00% to 17.95February 4, 2026 | msn.com60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 | msn.com60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipFebruary 2, 2026 | globenewswire.com60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseJanuary 29, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 | msn.com60 Degrees Pharmaceuticals stock tumbles after Nasdaq delisting noticeJanuary 26, 2026 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOR, CDT, ENSC, and SXTP Company DescriptionsBiora Therapeutics NASDAQ:BIORBiora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.CDT Equity NASDAQ:CDT$0.74 -0.03 (-4.26%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.08%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Ensysce Biosciences NASDAQ:ENSC$0.25 +0.00 (+0.40%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$0.25 0.00 (-1.18%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.39 -0.04 (-2.80%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
